Table 7: Adjusted OR after multivariate analysis for predictors of treatment outcome of mortality/death (N=332).

Characteristics Died Other treatment categories aOR(95% CI)p-value
N (%)N (%)

Cavitary lesions on CXR (N=279)
 (i) Yes8(12.5)56(87.5)0.55(0.34-0.91)0.019
 (ii) No29(13.7)182(86.3)
Smoking (N=177)
 (i) Yes24(31.6)52(68.4)2.31(1.35-5.01)0.043
 (ii) No14(12.8)95(87.2)
Baseline positive sputum smear (N=268)
 (i) Yes33(16.0)173(84.0)1.24(0.48-3.21)0.661
 (ii) No13(14.9)74(85.1)
Baseline positive sputum culture (N=253)
 (i) Yes16(10.5)136(89.5)0.55(0.23-1.34)0.190
 (ii) No17(17.3)81(82.7)
HIV status
 (i) Yes22(19.5)91(80.5)1.10(0.49-2.50)0.815
 (ii) No34(15.9)180(84.1)
Diabetes (N=319)
 (i) Yes1(20.0)4(80.0)1.49(0.33-6.71)0.609
 (ii) No52(16.8)258(83.2)
Isoniazid
 (i) Resistant17(13.3)111(86.7)0.77(0.24-2.46)0.661
 (ii) susceptible1(9.1)10(90.9)
Rifampicin
 (i) Resistant33(16.7)165(83.3)1.27(0.50-3.22)0.614
 (ii) Susceptible0(0.0)5(100.0)
Streptomycin
 (i) Resistant12(14.8)67(85.2)0.54(0.10-2.78)0.459
 (ii) Susceptible1(3.0)32(97.0)
Ethambutol
 (i) Resistant11(15.3)61(84.7) 0.97(0.20-4.68) 0.974
 (ii) Susceptible2(5.6)34(94.4)